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In the 1930s, the Hungarian scientists Rusznyak and Szent-Györgi identified a substance from lemon peels that reduced capillary permeability and that was an effective treatment in purpura patients who were resistant to vitamin C therapy (1) . They called this substance "vitamin P" (P for permeability). Later, Bruckner and Szent-Györgyi (2) reported that this "vitamin P" (or citrin) was not a pure substance but that it consisted of a mixture of the flavonoids hesperidin and eriodictyol glucoside. Flavonoids are water-soluble plant pigments that are characterized by an aromatic ring structure with one or more hydroxyl groups. They belong to the larger group of plant (poly)phenols, which can be divided into 10 different subclasses, including flavonols, catechins, (pro)anthocyanidins, lignans, and lignins (3) . Polyphenols occur in all plant foods and may contribute to the beneficial health effects of vegetables and fruit. Their contribution to the antioxidant capacity of the human diet is much larger than that of vitamins. More than 6000 different flavonoids in plants have been described, and their total intake could amount to 1 g/d, whereas combined intakes of ␤-carotene, vitamin C, and vitamin E from food most often are 100 mg/d (4) . Important dietary sources of flavonoids in Western societies are onions (flavonols); cocoa (proanthocyanidins); tea, apples, and red wine (flavonols and catechins); citrus fruit (flavanones); berries and cherries (anthocyanidins); and soy (isoflavones).
Flavonoids lost their vitamin status in the 1950s and became suspected of carcinogenicity (mainly, quercetin) in the 1970s. In the late 1980s, however, their tainted reputation was repaired and they were considered to be anticarcinogenic. It was only in the 1990s that the Dutch research group led by Kromhout reported a strong protective effect of several flavonols-ie, quercetin, kaempferol, and myricitin-against mortality due to coronary heart disease in the Zutphen Elderly Study (5) . The risk of coronary death in this cohort was reduced by as much as 70% in men who consumed 30 mg flavonols/d. A later analysis in the Rotterdam Study among 4807 older Dutch men and women confirmed these findings, with a 65% lower risk for fatal myocardial infarction in subjects whose flavonol intake was 33 mg/d, mainly from tea (6) . In the cohort of Dutch men in the Zutphen Study, flavonol intake was also related to a 70% lower risk of incident stroke (7) . Epidemiologic studies of flavonoids and cardiovascular mortality have also been performed in other countries, and in most, although not all, studies, a protective association was found (3, 8) . The strong risk reductions that were observed in the Dutch cohorts, however, could not be reproduced. The meta-analysis by Huxley and Neil in 2003 that comprised 7 cohort studies from the United Kingdom, United States, Finland, and the Netherlands yielded a pooled relative risk for incidence of coronary heart disease of 0.80 (95% CI: 0.69, 0.93); the relative risks varied between 0.6 and 1.6 for high and low flavonol intake, respectively, in non-Dutch cohorts (8) . The discrepancy in the strength of the associations may be due to measurement error for true flavonol exposure, because dietary assessment methods and major dietary sources of flavonols (with large variations in bioavailability) differ between countries. Most epidemiologic studies used the tables published by Hertog et al (5) that showed flavonol content of foods and drinks in the Netherlands, which may not be directly applicable to other countries. In addition, confounding by differences in socioeconomic status, other dietary compounds, and lifestyle factors among populations could have played a role.
After the reports by Kromhout's group, research into possible biological pathways that could underlie the vasoprotective properties of dietary flavonoids in humans got a boost. A wealth of flavonoid studies using biomarkers of cardiovascular risk appeared in the literature in the past decade. In this issue of the Journal, Hooper et al (9) provide a sorely needed comprehensive review of 133 flavonoid trials, which they attempted to include in a meta-analysis. They aimed at determining the optimal doses of flavonoids and food sources for cardiovascular risk reduction and at setting priorities for future research. The main outcomes would not surprise researchers in the field-namely, that polyphenol-rich cocoa reduces blood pressure by 6 (systolic) and 3 (diastolic) mm Hg and that soy protein, which is rich in isoflavones, reduces LDL cholesterol by 0.2 mmol/L. Similar findings, although somewhat smaller, have also been reported by Taubert et al (10) in a meta-analysis of randomized controlled trials of cocoa polyphenols and blood pressure and by Taku et al (11) in a meta-analysis of soy isoflavones and blood lipids. Hooper et al also showed that black tea acutely raises blood pressure by 6 (systolic) and 3 (diastolic) mm Hg, whereas chocolate acutely increases flow-mediated dilation by 4%. Although the latter findings are interesting from a physiologic point of view, such changes could be reversible, and acute effects are not easily translated into long-term risks of disease. Meta-analysis of chronic tea intake did not show significant effects on blood pressure (9, 10) . Acute effects of tea may also be due to other substances, eg, caffeine, rather than flavonoids.
This brings us to a drawback of the review by Hooper et al-namely, that a distinction between trials with isolated flavonoids and those with flavonoid-rich products cannot be made easily (if at all). Most of the trials included flavonoid-rich products, whereas only Ȃ10 trials were based on isolated flavonoids. Thus, it remains unclear whether the measured effect on cardiovascular biomarkers could actually be attributed to the targeted flavonoid(s). Chocolate and cocoa contain a rich mixture of (poly)phenols such as the flavonoid class of proanthocyanidins, which itself contains many different compounds. Apart from that, plant-derived foods such as tea and cocoa also contain other substances that could exert an effect on the cardiovascular system, such as theobromine, tryptophan, caffeine, and minerals such as potassium and magnesium.
This meta-analysis shows the state of the art in flavonoid and cardiovascular research. As Hooper et al stated, no randomized controlled trials have studied the effects of flavonoids on clinical cardiovascular endpoints. However, a number of trials of acceptable quality with flavonoid-rich foods provide evidence for a beneficial effect on flow-mediated dilation, blood pressure, and lipid profile, which are relevant indicators of cardiovascular health. Substantial evidence for a vasoprotective effect of specific flavonoids is, however, still lacking. Optimal doses of specific flavonoids for cardiovascular protection, one of the aims of the review, are still beyond the horizon. Flavonoid research has made large progress since the days of Szent-Györgi, but, to really advance the field, the step to individual flavonoids must be made now.
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